Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 26 November 2020

 
 
 
   

Will the EU Pharmaceutical Strategy help Europe become a world leader in medical innovation once again?

 
EFPIA Response to the EU Pharmaceutical Strategy

Published today, the EU Pharmaceutical Strategy contains a number of proposals that can help Europe stem the 25-year trend of cutting-edge science and investment leaving Europe for the US and China. But choosing the right policy option to address the right issue will be critical to prevent further loss of competitiveness as the EU endeavours to regain its position as a world leader in medical innovation.

We welcome the recognition in the EU Pharmaceutical Strategy of the critical importance of incentives in driving research into areas of unmet medical need. Learning the lessons from the COVID-19 crisis, the inclusion in the Strategy of a series of measures to tackle antimicrobial resistance, (...)

Read more


 
 
 
   

Statements

 

EFPIA statement on the IP Action Plan
25 November 2020

The COVID-19 crisis has clearly demonstrated that IP has driven and enabled the unprecedented research response leading... Read more

EFPIA e4ethics merge with the MedTech Europe Conference Vetting System
24 November 2020

Starting on 1st January 2021, the two trade associations will have a common platform assessing their conferences. Read more

 
 
 
   

Blogs

 

Podcast: Can we develop better medicines for children faster?
26 November 2020

Welcome to 19 conversations Read more

Bringing stakeholders together to improve patient access to oncology therapies in Europe (Guest...
26 November 2020 - Bas Amesz - Christel Jansen

Every Day Counts: Accelerate Access, Beat Cancer Read more

Can we move towards earlier diagnosis for Alzheimer’s? (Guest blog)
26 November 2020 - Laura Campo

If a new medicine can successfully slow the damage done by this progressive disease, early detection and timely diagnosis... Read more

IMI Impact: reinventing regulatory science, together (Guest blog)
24 November 2020 - Judith Macdonald - Nick Sykes

Industry and regulators are collaborating to modernise how medicines are developed, making research more relevant to... Read more

Implementing integrated diabetes systems in Europe
20 November 2020

The enabling role of integrated finance and IT Read more

 
 
 
   

Videos

 

Why has the Paediatric Regulation been successful?
Listen to Hubert Caron, iPODD Pediatric Oncology Team, Hoffmann La Roche Read more

What are you currently doing to improve treatment options for children with cancer?
Listen to Peter Adamson, Therapeutic Area Head Oncology Development and Pediatric Innovation, Sanofi Read more

 
 
 
   

Events

 

Together against Cancer: How can Europe benefit from breakthroughs in personalised oncology?...
30 November 2020 (Virtual event)

Join us on 30 November for an event that you can personalise Read more

How to turn around the increasing burden of cardiovascular disease in Europe?
08 December 2020 (Virtual event)

Virtual event jointly organised by the European Heart Network and EFPIA Read more

FAIRplus webinar: What is the value of FAIR data?
09 December 2020 (Virtual event)

Using real life examples and use cases, this online event will showcase the value of FAIR data in pharmaceutical research... Read more

34th International Conference of Alzheimer’s Disease International
10 December 2020 (Virtual event)

Hope in the Age of Dementia New science. New knowledge. New solutions. Read more

 
 
 
   

What we are reading

 

Expensive health?
On 20 November 2020 (Elements)

A debate between Nathalie Moll and Dr. Carlos Correa, head of a think tank in Geneva that represents the interests of... Read more

Time to focus on EU’s third largest Member State: that of people with diabetes
On 20 November 2020 (Euractiv)

By Milena Richter | EFPIA and Sanofi Read more

Antimicrobial resistance is the next battle
On 13 July 2020 (Financial Times)

By Emma Walmsley, chief executive of GSK Read more